EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

Ming Teng, Xiaomin Luo, Peng Zhang, Chen Yang, Yuniel Ma, Xinhua Liu

BMEMat · 2026-09 · 4 (3)

DOI: 10.1002/bmm2.70066 ↗
AbstractBibliografische Angaben

Abstract

Abstract The rising global incidence of inflammatory bowel disease (IBD) is strongly linked to gut microbiota dysbiosis driven by modern lifestyle factors, particularly dietary irregularities and antibiotic overuse. Probiotic supplementation represents a promising therapeutic strategy for microbiota modulation; specifically, Lactobacillus reuteri has been shown to improve microbial community structure, suppress colonization by pathogens, and mitigate intestinal disorders. This study introduces a hierarchically structured double‐encapsulated probiotic system, termed “core–shell” AMS@Eud, which integrates calcium alginate microspheres with a Eudragit® resin coating. This design enables pH‐responsive release and ensures superior protection of probiotic viability. After optimization, AMS@Eud demonstrated outstanding storage stability, with only 5.28% and 9.09% reduction in L. reuteri viability after 35 days at 4°C and 25°C, respectively, thereby eliminating the need for cold‐chain logistics. Under simulated gastrointestinal conditions, the system maintained a high viability of 84.60 ± 2.59% for L. reuteri , whereas free probiotics were entirely inactivated. A comprehensive bio‐safety evaluation confirmed its excellent biocompatibility and minimal hemolytic activity, with in vivo studies revealing no adverse effects on major organs. Furthermore, this platform significantly enriched beneficial gut microbes while reducing pro‐inflammatory taxa, effectively overcoming two major limitations of conventional probiotic therapy. Thus, AMS@Eud provides a transformative strategy for IBD management through precision microbiota engineering.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →